Literature DB >> 22633653

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

Peter K Smith1, Lawrence T Goodnough, Jerrold H Levy, Robert S Poston, Mary A Short, Govinda J Weerakkody, Leroy A Lenarz.   

Abstract

OBJECTIVES: The objective of this study was to characterize the bleeding, transfusion, and other outcomes of patients related to the timing of prasugrel or clopidogrel withdrawal before coronary artery bypass grafting (CABG).
BACKGROUND: There is little evidence to guide clinical decision making regarding the use of prasugrel in patients who may need urgent or emergency CABG. Experience with performing CABG in the presence of clopidogrel has raised concern about perioperative bleeding complications that are unresolved.
METHODS: A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346). A supplemental case report form was designed and administered, and the data combined with the existing TRITON-TIMI 38 database. Baseline imbalances were corrected for using elements of the European System for Cardiac Operative Risk Evaluation and The Society of Thoracic Surgeons predictive algorithm.
RESULTS: A significantly higher mean 12-h chest tube blood loss (655 ± 580 ml vs. 503 ± 378 ml; p = 0.050) was observed with prasugrel compared with clopidogrel, without significant differences in red blood cell transfusion (2.1 U vs. 1.7 U; p = 0.442) or the total donor exposure (4.4 U vs. 3.0 U; p = 0.463). All-cause mortality was significantly reduced with prasugrel (2.31%) compared with 8.67% with clopidogrel (adjusted odds ratio: 0.26; p = 0.025).
CONCLUSIONS: Despite an increase in observed bleeding, platelet transfusion, and surgical re-exploration for bleeding, prasugrel was associated with a lower rate of death after CABG compared with clopidogrel.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633653      PMCID: PMC3407327          DOI: 10.1016/j.jacc.2012.03.030

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  Antiplatelet therapy and coronary artery bypass graft surgery a fallow land.

Authors:  Gilles Montalescot; Jean-Sébastien Hulot; Jean-Philippe Collet
Journal:  J Am Coll Cardiol       Date:  2010-12-07       Impact factor: 24.094

Review 2.  A review of topical hemostatic agents for use in cardiac surgery.

Authors:  James Barnard; Russell Millner
Journal:  Ann Thorac Surg       Date:  2009-10       Impact factor: 4.330

3.  Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.

Authors:  Sary F Aranki; Simon C Body
Journal:  J Thorac Cardiovasc Surg       Date:  2009-10       Impact factor: 5.209

4.  2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Frederick G Kushner; Mary Hand; Sidney C Smith; Spencer B King; Jeffrey L Anderson; Elliott M Antman; Steven R Bailey; Eric R Bates; James C Blankenship; Donald E Casey; Lee A Green; Judith S Hochman; Alice K Jacobs; Harlan M Krumholz; Douglass A Morrison; Joseph P Ornato; David L Pearle; Eric D Peterson; Michael A Sloan; Patrick L Whitlow; David O Williams
Journal:  Circulation       Date:  2009-11-18       Impact factor: 29.690

5.  2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.

Authors:  R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; James Patrick Zidar
Journal:  J Am Coll Cardiol       Date:  2011-05-10       Impact factor: 24.094

6.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.

Authors:  Claes Held; Nils Asenblad; Jean Pierre Bassand; Richard C Becker; Christopher P Cannon; Marc J Claeys; Robert A Harrington; Jay Horrow; Steen Husted; Stefan K James; Kenneth W Mahaffey; José C Nicolau; Benjamin M Scirica; Robert F Storey; Marius Vintila; Joseph Ycas; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2010-12-30       Impact factor: 24.094

7.  Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.

Authors:  A M Lincoff; L A LeNarz; G J Despotis; P K Smith; J E Booth; R E Raymond; S K Sapp; C F Cabot; J E Tcheng; R M Califf; M B Effron; E J Topol
Journal:  Ann Thorac Surg       Date:  2000-08       Impact factor: 4.330

8.  Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.

Authors:  Jean-Pierre Bassand; Rizwan Afzal; John Eikelboom; Lars Wallentin; Ron Peters; Andrzej Budaj; Keith A A Fox; Campbell D Joyner; Susan Chrolavicius; Christopher B Granger; Shamir Mehta; Salim Yusuf
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

9.  Clopidogrel use and bleeding after coronary artery bypass graft surgery.

Authors:  John Hyung-Jun Kim; L Kristin Newby; Robert M Clare; Linda K Shaw; Andrew J Lodge; Peter K Smith; E Marc Jolicoeur; Sunil V Rao; Richard C Becker; Daniel B Mark; Christopher B Granger
Journal:  Am Heart J       Date:  2008-09-21       Impact factor: 4.749

10.  Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Authors:  Ramin Ebrahimi; Cornelius Dyke; Roxana Mehran; Steven V Manoukian; Frederick Feit; David A Cox; Bernard J Gersh; E Magnus Ohman; Harvey D White; Jeffrey W Moses; James H Ware; A Michael Lincoff; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2009-05-26       Impact factor: 24.094

View more
  30 in total

Review 1.  Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?

Authors:  Christoph Varenhorst; Stefan James
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

Review 2.  [Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].

Authors:  C B Olivier; P Diehl; C Bode; M Moser
Journal:  Herz       Date:  2014-11       Impact factor: 1.443

Review 3.  Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.

Authors:  Ana Lucrecia Marcano; José Luis Ferreiro
Journal:  Curr Atheroscler Rep       Date:  2016-11       Impact factor: 5.113

Review 4.  Highlights of the year in JACC 2012.

Authors:  Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2013-01-22       Impact factor: 24.094

5.  Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.

Authors:  Lawrence T Goodnough; Peter K Smith; Jerrold H Levy; Robert S Poston; Mary A Short; Govinda J Weerakkody; LeRoy A LeNarz
Journal:  J Thorac Cardiovasc Surg       Date:  2012-09-17       Impact factor: 5.209

6.  Hospital Variability Drives Inconsistency in Antiplatelet Use After Coronary Bypass.

Authors:  Jared P Beller; William Z Chancellor; J Hunter Mehaffey; Robert B Hawkins; Matthew R Byler; Alan M Speir; Mohammed A Quader; Andy C Kiser; Leora T Yarboro; Gorav Ailawadi; Nicholas R Teman
Journal:  Ann Thorac Surg       Date:  2020-02-11       Impact factor: 4.330

7.  Thrombocytopenia After Cardiopulmonary Bypass Is Associated With Increased Morbidity and Mortality.

Authors:  Benjamin R Griffin; Michael Bronsert; T Brett Reece; Jay D Pal; Joseph C Cleveland; David A Fullerton; Katja M Gist; Anna Jovanovich; Diana Jalal; Sarah Faubel; Muhammad Aftab
Journal:  Ann Thorac Surg       Date:  2019-12-06       Impact factor: 4.330

Review 8.  Novel antiplatelet agents in acute coronary syndrome.

Authors:  Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2014-10-07       Impact factor: 32.419

Review 9.  Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications.

Authors:  Rahul R Goli; Mayur M Contractor; Ashwin Nathan; Sony Tuteja; Taisei Kobayashi; Jay Giri
Journal:  Curr Atheroscler Rep       Date:  2017-11-04       Impact factor: 5.113

Review 10.  The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

Authors:  Dominick J Angiolillo
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.